Table 3 Association of intensity of p53 overexpression with various clinical & pathological parameters
From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
n (%) | P-Value | |||||
|---|---|---|---|---|---|---|
Weak (n = 21) | Intermediate (n = 26) | Strong (n = 57) | Negative (n = 46) | Total (n = 150) | ||
Age groups | ||||||
≤ 30 years | 0 (0) | 0 (0) | 3 (5.3) | 2 (4.3) | 5 (3.3) | 0.347 |
31–50 years | 8 (38.1) | 14 (53.8) | 34(59.6) | 28 (60.9) | 84 (56) | |
> 50 years | 13 (61.9) | 12 (46.2) | 20 (35.1) | 16 (34.8) | 61 (40.7) | |
Tumor stage/tumor size | ||||||
T1 (≤2 cm) | 6 (28.6) | 5 (19.2) | 14 (24.6) | 1 (2.2) | 26 (17.3) | 0.023 |
T2 (2.1–5.0 cm) | 9 (42.9) | 12 (46.2) | 29 (50.9) | 29 (63) | 79 (52.7) | |
T3 (> 5.0 cm) | 6 (28.6) | 9 (34.6) | 14 (24.6) | 16 (34.8) | 45 (30) | |
ki67 index groups | ||||||
≤ 15% | 5 (23.8) | 8 (30.8) | 1 (1.8) | 3 (6.5) | 17 (11.3) | 0.006 |
16–24% | 1 (4.8) | 2 (7.7) | 3 (5.3) | 2 (4.3) | 8 (5.3) | |
25–44% | 7 (33.3) | 7 (26.9) | 16 (28.1) | 15 (32.6) | 45 (30) | |
> 44% | 8 (38.1) | 9 (34.6) | 37 (64.9) | 26 (56.5) | 80 (53.3) | |
Nodal Status | ||||||
Positive | 9 (42.9) | 13 (50) | 21 (36.8) | 21 (45.7) | 64 (42.7) | 0.675 |
Negative | 12 (57.1) | 13 (50) | 36 (63.2) | 25 (54.3) | 86 (57.3) | |
Nodal Stage | ||||||
No | 12 (57.1) | 13 (50) | 36 (63.2) | 27 (58.7) | 88 (58.7) | 0.357 |
N1 | 5 (23.8) | 7 (26.9) | 8 (14) | 10 (21.7) | 30 (20) | |
N2 | 0 (0) | 5 (19.2) | 5 (8.8) | 3 (6.5) | 13 (8.7) | |
N3 | 4 (19) | 1 (3.8) | 8 (14) | 6 (13) | 19 (12.7) | |
Histological Subtypes | ||||||
IDC | 17 (81) | 21 (80.8) | 50 (87.7) | 39 (84.8) | 127 (84.7) | 0.620 |
Papillary | 1 (4.8) | 1 (3.8) | 3 (5.3) | 1 (2.2) | 6 (4) | |
Medullary | 0 (0) | 1 (3.8) | 0 (0) | 0 (0) | 1 (0.7) | |
metaplastic | 2 (9.5) | 3 (11.5) | 3 (5.3) | 6 (13) | 14 (9.3) | |
Mixed | 1 (4.8) | 0 (0) | 1 (1.8) | 0 (0) | 2 (1.3) | |
Tumor Grade | ||||||
Grade-I | 1 (4.8) | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | 0.041 |
Grade-II | 6 (28.6) | 4 (15.4) | 6 (10.5) | 3 (6.5) | 19 (12.7) | |
Grade-III | 14 (66.7) | 22 (84.6) | 51 (89.6) | 43 (93.5) | 130 (86.7) | |
Lymhovascular Invasion | ||||||
Present | 7 (33.3) | 6 (23.1) | 15 (26.3) | 8 (17.4) | 36 (24) | 0.516 |
Absent | 14 (66.7) | 20 (76.9) | 42 (73.7) | 38 (82.6) | 114 (76) | |
Perinodal extension | ||||||
Present | 5 (23.8) | 3 (11.5) | 15 (26.3) | 7 (15.2) | 30 (20) | 0.352 |
Absent | 16 (76.2) | 23 (88.5) | 42 (73.7) | 39 (84.8) | 120 (80) | |
Triple Negative phenotype | ||||||
Basal | 3 (14.3) | 3 (11.5) | 5 (8.8) | 5 (10.9) | 16 (10.7) | 0.913 |
Non Basal | 18 (85.7) | 23 (88.5) | 52 (91.2) | 41 (89.1) | 89.3) | |